Introduction {#s1}
============

Primary sleep disorders are those not associated with a medical condition, substance use or concurrent psychological disorder. In order to be diagnosed with a primary sleep disorder, the sleep disturbance must cause significant distress or impairment in social, occupational, or other areas of functioning [@pone.0063773-AmericanPsychiatric1]. Nine percent of Americans report having insomnia [@pone.0063773-National1]. Thirty-five to forty percent of Americans report having problems falling asleep or excessive daytime sleepiness [@pone.0063773-Hossain1]. Primary sleep disorders are often comorbid with psychiatric disorders, neurological and cardiovascular diseases [@pone.0063773-Dikeos1]. Average medical expenses of individuals with insomnia in the United States is nearly \$2000 greater annual than those without sleep problems [@pone.0063773-Ozminkowski1]. Poor sleep is also associated with an increased risk of mortality, hospitalization and traffic accidents [@pone.0063773-Ellen1]--[@pone.0063773-Leger1].

First line treatment options for primary sleep disorders often include psychological or behavioral therapies [@pone.0063773-Morgan1]. Sleep hygiene, sleep restriction, stimulus control, relaxation training and cognitive therapy are examples of such non-pharmacological therapies, all of which have shown some evidence of efficacy [@pone.0063773-Morin1]--[@pone.0063773-Smith1]. Pharmacological treatments for primary sleep disorders, like insomnia, include benzodiazepine receptor agonists, benzodiazepines, sedating antidepressants and other drugs with sedating feature (anxiolytics, antipsychotics, antihistamines). Side-effects vary between these medications and can range from residual daytime sleepiness to dependence [@pone.0063773-Srinivasan1]. There are many over-the-counter medications and herbal therapies that are used by individuals to treat insomnia. However the efficacy and side-effect profile of these substances are not as well known or studied as prescription medications [@pone.0063773-Morin2].

Many trials have been performed to assess the efficacy of exogenous melatonin in treating primary sleep disorders. Melatonin is a hormone secreted primarily by the pineal gland in response to variations in the circadian cycle and has been used for the last two decades for the treatment of sleep disorders in adults and children [@pone.0063773-Claustrat1]. In contrast to most available sleep medications, melatonin has little dependence potential, is not associated with habituation and typically produces no hangover. Given its reported hypnotic effects, relatively benign side-effect profile and over-the-counter availability, melatonin has been widely utilized in the United States [@pone.0063773-Bliwise1].

A previous meta-analysis demonstrated that melatonin was beneficial in treating most primary sleep disorders over the short-term (4 weeks or less) [@pone.0063773-Buscemi1]. However, since this meta-analysis, 7 trials have been published with an additional 1258 subjects. These additional trials nearly triple the sample size of previous meta-analyses. The additional power provided by these new trials will (1) allow us to more precisely estimate measures of treatment effects and (2) examine moderators of melatonin efficacy. Specifically, we will examine melatonin's effects on sleep latency, total sleep time and sleep quality. We will also examine the moderating effects of measure type, dose and duration of melatonin treatment.

Methods {#s2}
=======

Selection of Studies {#s2a}
--------------------

PubMed was searched by two reviewers (AQ and EFO) using the terms "Melatonin" and "Sleep Disorder". The search was further limited to include only randomized controlled trials and meta-analyses. The bibliographies of related reviews, meta-analyses and included articles were searched for additional eligible citations. All studies included were published before or on March 2012.

Inclusion Criteria {#s2b}
------------------

Trials were included if they (1) analyzed primary sleep disorders as defined by the DSM-IV, (2) examined the effects of melatonin, (3) were randomized placebo controlled trials, (4) had at least 10 participants for parallel designs or 5 participants for crossover designs and (5) were published in English. Disagreements regarding the inclusion of studies were discussed between the two reviewers (AQ and EFO) and ultimately decided by the third reviewer (MHB) when necessary.

Meta-analytic Procedures {#s2c}
------------------------

Data was extracted using Microsoft Excel spreadsheets. Extracted data included sleep onset latency, total sleep time, sleep quality, age of sample, dose, duration, drug formulation. Sleep onset latency, total sleep time and sleep quality data were also classified in objective measures (polysomnography or actigraphy) and/or subjective (scales, questionnaires, sleep logs).

Our primary outcome measure was mean improvement in sleep onset latency, total sleep time and sleep quality. In this meta-analysis, we considered sleep efficacy the same as sleep quality. We examined the difference between melatonin and placebo by calculating the weighted mean difference (WMD) using Comprehensive Meta-Analysis (Biostat, Englewood, NJ) for sleep latency and total sleep time analysis. Sleep quality was analyzed in Comprehensive Meta-Analysis by calculating the standardized mean difference (SMD). SMD was favored over WMD for measuring sleep quality because rating scales assessing sleep quality differed between the included studies. A fixed-effects model was used for this meta-analysis with the results for a random-effects model presented as a sensitivity analysis.

Publication bias was assessed by plotting the effect size against standard error for each trial (funnel plot) [@pone.0063773-Egger1]. In addition, publication bias was statistically tested by the Egger's test and by determining the association between sample size and effect size in meta-regression [@pone.0063773-Egger1]. Heterogeneity between trials was determined by means of two separate statistical estimates using Comprehensive Meta-Analysis. First, a *Q-*statistic was employed to provide a test of statistical significance indicating whether the differences in effect sizes are due to subject-level sampling error alone or other sources. In addition, we estimated heterogeneity using *I-square* statistic, which estimates the proportion of total variance that is attributable to between-study variance.

For secondary analyses we performed several subgroup analyses and meta-regressions. Stratified subgroup analysis was used to assess the effects of type of measure (subjective/objective). We used the test for subgroup differences in Comprehensive Meta-Analysis to determine whether subgroups reduced overall heterogeneity [@pone.0063773-Deeks1]. We initially intended to examine the effects of age group (children younger than 18 years old vs. adults older than 18 years old) on melatonin's effects. However, there were not enough trials in children to conduct this analysis. Meta-regression was performed to examine the association between melatonin efficacy in trials and continuous variables such as (1) dose and (2) duration. Our threshold for statistical significance was selected to be p\<.05 for the primary analysis, as well as for all subgroups analyses and meta-regression. Forest plots were generated separately on Microsoft Excel using previously published methods to aid in presentation of the results [@pone.0063773-Neyeloff1]. All data including information on the inclusion/exclusion of studies and extraction of data for meta-analysis is available from the corresponding author by request.

Results {#s3}
=======

Included Studies {#s3a}
----------------

We included nineteen studies involving a total of 1683 subjects in this meta-analysis [@pone.0063773-Buscemi2]--[@pone.0063773-Dahlitz1]. From the search on Pubmed and related bibliography above described 268 studies were selected. A total of 249 manuscripts were excluded for the following reasons: 123 were not randomized placebo controlled trials, 61 did not examine sleep disorders, 40 did not examine primary sleep disorders, thirteen did not examine the effects of melatonin, four did not have sample size fitting the inclusion criteria, five manuscripts were follow-up studies, two manuscripts were not in a peer-reviewed journal, and one study was retracted. Nineteen studies were included in the analysis, fourteen studies on the efficacy of melatonin for the treatment of insomnia, four studies on delayed sleep phase syndrome and one study on REM sleep behavior disorder. [Table 1](#pone-0063773-t001){ref-type="table"} depicts the characteristics of included studies in this meta-analysis.

10.1371/journal.pone.0063773.t001

###### Characteristics of Included Trials.

![](pone.0063773.t001){#pone-0063773-t001-1}

  Author                                              Year   Sample Size     Age          Duration                     Dose                    Design
  -------------------------------------------------- ------ ------------- ---------- ------------------ ----------------------------------- ------------
  Wade AG [@pone.0063773-Wade1]                       2011       746        Adults    21 days/182 days                  2mg                   Parallel
  Kunz D [@pone.0063773-Kunz1]                        2010        8         Adults        28 days                      3 mg                  Cross-over
  van Geijlswijk IM [@pone.0063773-vanGeijlswijk1]    2010       70        Children        7 days        0.05 mg/kg, 0.1 mg/kg, 0.15 mg/kg    Parallel
  Luthringer R [@pone.0063773-Luthringer1]            2009       40         Adults        56 days                      2 mg                   Parallel
  Garzón C [@pone.0063773-Garzon1]                    2009       22         Adults        126 days                     5 mg                  Cross-over
  Lemoine P [@pone.0063773-Lemoine1]                  2007       170        Adults        21 days                      2 mg                   Parallel
  Wade AG [@pone.0063773-Wade2]                       2007       354        Adults        21 days                      2 mg                   Parallel
  Mundey K [@pone.0063773-Mundey1]                    2005       13         Adults        28 days                 0.3 mg or 3 mg              Parallel
  Smits MG [@pone.0063773-Smits1]                     2003       62        Children       28 days                      5 mg                   Parallel
  Almeida Montes LG [@pone.0063773-AlmeidaMontes1]    2002       10         Adults        21 days                  0.3 mg, 1 mg              Cross-over
  Kayumov L [@pone.0063773-Kayumov1]                  2001       22         Adults        28 days                      5 mg                  Cross-over
  Smits MG [@pone.0063773-Smits2]                     2001       40        Children       28 days                      5 mg                   Parallel
  Zhdanova IV [@pone.0063773-Zhdanova1]               2001       30         Adults        28 days              0.1 mg, 0.3 mg, 1 mg          Cross-over
  Dawson D [@pone.0063773-Dawson1]                    1998       12         Adults         8 days                     0.5 mg                 Cross-over
  Nagtegaal JE [@pone.0063773-Nagtegaal1]             1998       25         Adults        28 days                      5 mg                  Cross-over
  Ellis CM [@pone.0063773-Ellis1]                     1996       15         Adults         7 days                      5 mg                  Cross-over
  Haimov I [@pone.0063773-Haimov1]                    1995       26         Adults         7 days                      2 mg                   Parallel
  Dahlitz M [@pone.0063773-Dahlitz1]                  1991        8         Adults        28 days                      5 mg                  Cross-over
  James SP [@pone.0063773-James1]                     1989       10         Adults        14 days                   1 mg, 5 mg               Cross-over

Sleep Onset Latency {#s3b}
-------------------

Our meta-analysis demonstrated melatonin had a significant benefit in reducing sleep latency. Subjects randomly assigned to melatonin fell asleep 7 minutes earlier on average than subjects receiving placebo (weighted mean difference (WMD) = 7.06 minutes \[95% CI: 4.37 to 9.75\], Z = 5.15, p\<0.001). [Figure 1](#pone-0063773-g001){ref-type="fig"} illustrates a forest plot depicting the estimated efficacy of melatonin from individual trials. There was significant evidence of heterogeneity between trials (Q = 31.9, df = 14, p = 0.004, I^2^ = 56%). In the random effects model, sleep latency was reduced by over 10 minutes (WMD = 10.18 minutes \[95% CI: 6.1 to 14.27\], Z = 4.88, p\<0.001). We found no significant evidence of publication bias based on the Egger's Test (intercept = 1.08, \[95% CI: −0.35 to 2.52\], t = 1.62, p = 0.12). Stratifying trials by objective and subjective measures of sleep onset did not significantly reduce heterogeneity between trials (Q = 3, df = 1, p = 0.08). Melatonin significantly reduced sleep latency on both objective (WMD = 5.50 minutes \[95% CI = 2.29 to 8.71\], Z = 3.36, p\<0.001) and subjective measures (WMD = 10.68 minutes \[95% CI: 5.78 to 15.58\], z = 4.27, p\<0.001). Meta-regression demonstrated that trials of longer duration (parameter estimate (PE) = 0.53 \[95% CI = 0.21 to 0.86\], p = 0.001) reported greater effects on sleep latency. Trials using higher doses of melatonin also reported greater effects of melatonin on sleep latency at trend levels (PE = 1.95 \[95% CI = −0.00 to 3.91\], p = 0.05).

![Efficacy of Melatonin in Reducing Sleep Latency.\
Forest plot depicting reduction of sleep latency in melatonin compared to placebo. Meta-analysis demonstrated a significant benefit of melatonin in reducing sleep latency. WMD = weighted mean difference; CI = confidence interval.](pone.0063773.g001){#pone-0063773-g001}

Total Sleep Time {#s3c}
----------------

Melatonin also significantly increased total sleep time compared to placebo. Subjects randomly assigned to melatonin had on average a total sleep time 8 minutes longer than subjects taking placebo (WMD = 8.25 minutes \[95% CI: 1.74 to 14.75\], Z = 2.48, p = 0.013). [Figure 2](#pone-0063773-g002){ref-type="fig"} illustrates a forest plot depicting the estimated efficacy of melatonin in individual trials. There was significant evidence of heterogeneity between trials (Q = 21.44, df = 12, p = 0.044, I^2^ = 44%). Total sleep time was increased by 8 minutes in the random effects model (WMD = 8.48 minutes \[95% CI: −4.02 to 20.98\], Z = 1.33, p = 0.184). We found no evidence of publication bias based on the Egger's Test (intercept = 0.3 \[95% CI: −0.9 to 1.7\], t = 0.6, p = 0.52). Stratifying trials by whether objective or subjective measures of total sleep time were utilized reduced heterogeneity at trend levels (Q = 2.6, df = 1, p = 0.10). Melatonin significantly increased total sleep time on subjective measures (WMD = 11.93 minutes \[95% CI: 4.06 to 19.81\], Z = 2.91, p = 0.002) but did not on objective measures (WMD = 0.33 minutes \[95% CI: −11.19 to 11.87\], Z = 0.05, p = 0.95). Meta-regression demonstrated that trials of longer duration (PE = 1.60 \[95% CI: 0.50 to 2.69\], p = 0.004) reported greater effects on total sleep time, as well as trials using higher doses of melatonin (PE = 7.25 \[95% CI: 1.94 to 12.56\], p = 0.007).

![Efficacy of Melatonin in Increasing Total sleep Time.\
Forest plot depicting change in total sleep time with melatonin compared to placebo treatment. Meta-analysis demonstrated a significant benefit of melatonin in increasing total sleep time. WMD = weighted mean difference; CI = confidence interval.](pone.0063773.g002){#pone-0063773-g002}

Sleep Quality {#s3d}
-------------

Melatonin demonstrated a significant effect in improving sleep quality. Subjects randomly assigned to melatonin had improvements in sleep quality compared to placebo (standardized mean difference (SMD) = 0.22 \[95% CI: 0.12 to 0.32\], Z = 4.52, p\<0.001). [Figure 3](#pone-0063773-g003){ref-type="fig"} illustrates a forest plot depicting the estimated efficacy of melatonin from individual trials. No significant evidence of heterogeneity between trials was observed (Q = 11.59, df = 13, p = 0.56, I^2^ = 0). A random effects model provided the same overall effect. We found no significant evidence of publication bias based on the Egger's Test (intercept = −0.13 \[95% CI: −1.08 to 0.81\], t = 0.30, p = 0.76). Stratifying trials by objective and subjective measures of sleep quality did not reduce heterogeneity between trials (Q = 0.05, df = 1, p = 0.82). Melatonin improved sleep quality to a similar degree on both subjective (SMD = 0.23 \[95% CI: 0.12 to 0.34\], Z = 4.23, p\<0.001) and objective measures (SMD = 0.20 \[95% CI: −0.04 to 0.44\], Z = 1.61, p = 0.10). Meta-regression demonstrated no significant effects of trial duration (PE = 0.005 \[95% CI: −0.0006 to 0.012\], p = 0.08) or dose of melatonin on sleep quality (PE = 0.011 \[95% CI: −0.114 to 0.090\], p = 0.81).

![Effect of Melatonin on Sleep quality.\
Forest plot depicts sleep quality with melatonin compared to placebo. Meta-analysis demonstrated a significant benefit of melatonin in improving sleep quality. SMD = standardized mean difference; CI = confidence interval.](pone.0063773.g003){#pone-0063773-g003}

Discussion and Conclusion {#s4}
=========================

Our meta-analysis demonstrates that melatonin significantly improves sleep in subjects with primary sleep disorders compared to placebo. Melatonin reduces sleep-onset latency, increases total sleep time and improves overall sleep quality compared to placebo to a statistically significant degree. It should be noted that the improvements in sleep parameters in absolute terms were smaller than previous meta-analyses of benzodiazepines and newer non-benzodiazepine sleep medications. For instance, the reduction in sleep latency observed with melatonin in this meta-analysis, slightly less than 7 minutes, was less than sleep-latency reduction observed in previous meta-analyses of other available sleep medications. A previous meta-analysis demonstrated a significant benefit of benzodiazepines (10.0 to 19.6 minutes) and non-benzodiazepine sleep medicines (12.8 to 17 minutes) in reducing sleep-onset latency for primary sleep disorders [@pone.0063773-Buscemi2]. Thus prescription sleep medications are quite likely more effective than melatonin, although head-to-head trials could definitely alleviate any doubts regarding the relative efficacy of these agents.

Meta-regressions were performed to assess the relationship between effect, duration and dose. Higher melatonin doses and longer duration trials were related to significant greater effect sizes on sleep latency and total sleep time. These findings suggest that there is no evidence of the development of tolerance with melatonin use. This stands in contrast to other commonly used hypnotics such as benzodiazepines [@pone.0063773-Srinivasan1]. No greater effects in sleep quality were observed with melatonin dose or trial duration, suggesting that melatonin effects on sleep quality are constant for any duration or dose.

Given our findings, it is important to note some limitations of this meta-analysis. Due to the relatively small number of trials that met our inclusion criteria, our meta-regression analysis had limited power. This problem was exacerbated by one trial that contributed a very large weight to our overall findings [@pone.0063773-Wade1]. The relatively small number of trials also limits the ability of the Egger's Test to demonstrate publication bias. However there was no evidence of publication bias for all outcome measures on funnel plot as well. There were relatively few studies examining the efficacy of melatonin in children with primary sleep disorders and this precluded any stratified subgroup analysis based on age. The presence of mostly trials examining primary insomnia limited our ability to perform an analysis based on diagnoses.

Despite these limitations, this meta-analysis demonstrated that exogenous melatonin administered to subjects with primary sleep disorders modestly improved sleep parameters including sleep latency, total sleep time and sleep quality. This finding corroborates the results of a previous meta-analysis conducted in the area several years ago that also demonstrated a significant benefit of melatonin [@pone.0063773-Buscemi1]. The benefits of melatonin compared to placebo appear smaller than that of available prescription sleep medications. However, melatonin should be considered in clinical practice due to its benign side-effect profile, cost and limited evidence of habituation and tolerance. Further research is needed to examine the long-term benefits of sleep medications including the comparative efficacy of melatonin to common prescription sleep medication.
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